{"id":886147,"date":"2025-09-15T07:28:01","date_gmt":"2025-09-15T11:28:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-presents-ath434-201-phase-2-data-at-the-american-neurological-association-annual-meeting\/"},"modified":"2025-09-15T07:28:01","modified_gmt":"2025-09-15T11:28:01","slug":"alterity-therapeutics-presents-ath434-201-phase-2-data-at-the-american-neurological-association-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-presents-ath434-201-phase-2-data-at-the-american-neurological-association-annual-meeting\/","title":{"rendered":"Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting"},"content":{"rendered":"

\nATH434 demonstrated clinically meaningful efficacy in modifying disease progression and was well tolerated at both 50 and 75 mg doses
\n<\/h2>\n
\n

MELBOURNE, Australia and SAN FRANCISCO, Sept. 15, 2025 (GLOBE NEWSWIRE) — Alterity Therapeutics<\/u><\/a> (ASX: ATH, NASDAQ: ATHE) (\u201cAlterity\u201d or \u201cthe Company\u201d), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that data from the ATH434-201 randomized, double-blind Phase 2 clinical trial in Multiple System Atrophy (MSA) was presented at the 150th<\/sup> Annual Meeting of the American Neurological Association (ANA), held in Baltimore, MD.<\/p>\n

A poster, entitled, \u201cATH434 Slowed Disease Progression in a Phase 2 Study in Multiple System Atrophy,\u201d was presented by Daniel Claassen, M.D., M.S., Professor of Neurology at Vanderbilt University Medical Center and Coordinating Investigator for the ATH434-201 Phase 2 study. In the study, ATH434 demonstrated clinically meaningful efficacy in modifying disease progression at both 50 and 75 mg doses as well as target engagement by reducing iron accumulation in MSA affected brain regions. Analysis of the data has also shown that the baseline differences in disease severity between the arms largely explain different response in 50 mg and 75 mg treatment groups. ATH434 was well tolerated with similar adverse event rates as placebo, and no serious adverse events were attributed to study drug.<\/p>\n

\u201cPresenting at the ANA conference allowed us to showcase the findings from our Phase 2 double-blind study of ATH434 to leading researchers and clinicians focused on neurological diseases,\u201d\u00a0said David Stamler, M.D., Chief Executive Officer of Alterity. \u201cThe data continue to demonstrate meaningful clinical impact, including reduced disease severity on the MSA activities of daily living scale, improvements in core symptoms, and maintained function in the outpatient setting. These results reinforce the therapeutic potential of ATH434 as a disease modifying therapy and are generating continued optimism across the medical community.\u201d<\/p>\n

The poster presentation can be found on Alterity\u2019s website here<\/u><\/a>.<\/p>\n

\n About ATH434<\/strong>\n <\/p>\n

Alterity\u2019s lead candidate, ATH434, is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. ATH434 has been shown preclinically to reduce \u03b1-synuclein pathology and preserve neuronal function by restoring normal iron balance in the brain in preclinical models. As an iron chaperone, it has excellent potential to treat Parkinson\u2019s disease as well as various Parkinsonian disorders such as Multiple System Atrophy (MSA). Phase 1 studies have demonstrated the agent is well tolerated and achieved brain levels comparable to efficacious levels in animal models of MSA. Positive results from the randomized, double-blind, placebo-controlled Phase 2 clinical trial in patients with MSA demonstrated robust clinical efficacy, target engagement on key biomarkers, and a favorable safety profile. Positive data from a second Phase 2 open-label biomarker trial in patients with more advanced MSA reinforced these results. ATH434 has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA), and Orphan Drug Designation by the FDA and the European Commission for the treatment of MSA.<\/p>\n

\n About ATH434-201 Phase 2 Clinical Trial <\/strong>\n <\/p>\n

The ATH434-201 Phase 2 clinical trial is a randomized, double-blind, placebo-controlled investigation of 12 months treatment with ATH434 in patients with MSA. The study evaluated the efficacy, safety and pharmacokinetics of ATH434 as well as the effect of ATH434 on neuroimaging and protein biomarkers. Wearable sensors were employed to evaluate motor activities outside of the clinic. The study enrolled 77 adults who were randomly assigned to receive ATH434 50 mg or 75 mg twice daily or matching placebo. The data showed that, compared to placebo, ATH434 produced clinically and statistically significant improvement on the modified Unified Multiple System Atrophy Rating Scale (UMSARS) Part\u00a0I, a functional rating scale that assesses disability on activities of daily living affected in MSA. Additional efficacy assessments demonstrated improvement consistent with the positive UMSARS Part I findings including trends in improved motor performance on the Parkinson\u2019s Plus rating scale, the Clinical Global Impression of Severity Scale, and the Orthostatic Hypotension Symptom Assessment (a patient reported outcome). Wearable sensor data indicated that ATH434 also led to increased activity in an outpatient setting. Biomarkers were used to evaluate potential drug effect and target engagement relative to placebo. Both dose levels reduced iron accumulation in MSA affected brain regions with trends in preservation of brain volume. ATH434 was well tolerated with similar adverse event rates compared to placebo and no serious adverse events attributed to ATH434. Additional information on the Phase 2 trial can be found by ClinicalTrials.gov Identifier: NCT05109091<\/u><\/a>.<\/p>\n

\n About Multiple System Atrophy<\/strong>\n <\/p>\n

Multiple System Atrophy (MSA) is a rare, neurodegenerative disease characterized by failure of the autonomic nervous system and impaired movement. The symptoms reflect the progressive loss of function and death of different types of nerve cells in the brain and spinal cord. It is a rapidly progressive disease and causes profound disability. MSA is a Parkinsonian disorder characterized by a variable combination of slowed movement and\/or rigidity, autonomic instability that affects involuntary functions such as blood pressure maintenance and bladder control, and impaired balance and\/or coordination that predisposes to falls. A pathological hallmark of MSA is the accumulation of the protein \u03b1-synuclein within glia, the support cells of the central nervous system, and neuron loss in multiple brain regions. MSA affects at least 15,000 individuals in the U.S., and while some of the symptoms of MSA can be treated with medications, currently there are no drugs that are able to slow disease progression and there is no cure.1<\/sup><\/p>\n

\n 1<\/sup>
\n
\n Multiple System Atrophy | National Institute of Neurological Disorders and Stroke (nih.gov)<\/u>
\n <\/a>\n <\/p>\n

\n About Alterity Therapeutics Limited <\/strong>\n <\/p>\n

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living\u00a0with neurodegenerative diseases. The Company is initially focused on developing disease modifying therapies in Parkinson\u2019s disease and related disorders. Alterity has demonstrated clinically meaningful efficacy for its lead asset, ATH434, in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with Multiple System Atrophy (MSA), a rare and rapidly progressive Parkinsonian disorder. ATH434 recently reported positive data in its open label Phase 2 clinical trial in advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company\u2019s website at www.alteritytherapeutics.com<\/u><\/a>.<\/p>\n

\n Authorisation & Additional information<\/strong>
\n
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.<\/p>\n

\n Contacts:<\/strong>\n <\/p>\n

\n Investors<\/strong>
\n
Remy Bernarda
Investor Relations Advisory Solutions
ir@alteritytx.com<\/u><\/a>
+1 (415) 203-6386<\/p>\n

\n Media<\/strong>
\n
Casey McDonald
Tiberend Strategic Advisors, Inc.
cmcdonald@tiberend.com<\/u><\/a>
+1 (646) 577-8520<\/p>\n

\n Forward Looking Statements<\/strong>\n <\/p>\n

\n This press release contains \u201cforward-looking statements\u201d within the meaning of section 27A of the Securities Act of 1933 and section<\/em>
\n 21E<\/em>
\n of<\/em>
\n the<\/em>
\n Securities<\/em>
\n Exchange<\/em>
\n Act<\/em>
\n of<\/em>
\n 1934.<\/em>
\n The<\/em>
\n Company<\/em>
\n has<\/em>
\n tried<\/em>
\n to<\/em>
\n identify<\/em>
\n such<\/em>
\n forward-looking<\/em>
\n statements<\/em>
\n by<\/em>
\n use of such words as \u201cexpects,\u201d \u201cintends,\u201d \u201chopes,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201ccould,\u201d \u201cmay,\u201d \u201cevidences\u201d and \u201cestimates,\u201d and other similar expressions, but these words are not the exclusive means of identifying such<\/em>
\n statements.<\/em>\n <\/p>\n

\n Important<\/em>
\n factors<\/em>
\n that<\/em>
\n could<\/em>
\n cause<\/em>
\n actual<\/em>
\n results<\/em>
\n to<\/em>
\n differ<\/em>
\n materially<\/em>
\n from<\/em>
\n those<\/em>
\n indicated<\/em>
\n by<\/em>
\n such<\/em>
\n forward-looking<\/em>
\n statements are<\/em>
\n described<\/em>
\n in<\/em>
\n the<\/em>
\n sections<\/em>
\n titled<\/em>
\n \u201cRisk<\/em>
\n Factors\u201d<\/em>
\n in<\/em>
\n the<\/em>
\n Company\u2019s<\/em>
\n filings<\/em>
\n with<\/em>
\n the<\/em>
\n SEC,<\/em>
\n including<\/em>
\n its<\/em>
\n most<\/em>
\n recent<\/em>
\n Annual<\/em>
\n Report on<\/em>
\n Form<\/em>
\n 20-F<\/em>
\n as<\/em>
\n well<\/em>
\n as<\/em>
\n reports<\/em>
\n on<\/em>
\n Form<\/em>
\n 6-K,<\/em>
\n including,<\/em>
\n but<\/em>
\n not<\/em>
\n limited<\/em>
\n to<\/em>
\n the<\/em>
\n following:<\/em>
\n statements<\/em>
\n relating<\/em>
\n to<\/em>
\n the<\/em>
\n Company’s drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company’s<\/em>
\n drug<\/em>
\n development<\/em>
\n program,<\/em>
\n including,<\/em>
\n but<\/em>
\n not<\/em>
\n limited<\/em>
\n to,<\/em>
\n ATH434,<\/em>
\n and<\/em>
\n any<\/em>
\n other<\/em>
\n statements<\/em>
\n that<\/em>
\n are<\/em>
\n not<\/em>
\n historical facts.<\/em>
\n Such<\/em>
\n statements<\/em>
\n involve<\/em>
\n risks<\/em>
\n and<\/em>
\n uncertainties,<\/em>
\n including,<\/em>
\n but<\/em>
\n not<\/em>
\n limited<\/em>
\n to,<\/em>
\n those<\/em>
\n risks<\/em>
\n and<\/em>
\n uncertainties<\/em>
\n relating<\/em>
\n to<\/em>
\n the difficulties<\/em>
\n or<\/em>
\n delays<\/em>
\n in<\/em>
\n financing,<\/em>
\n development,<\/em>
\n testing,<\/em>
\n regulatory<\/em>
\n approval,<\/em>
\n production<\/em>
\n and<\/em>
\n marketing<\/em>
\n of<\/em>
\n the<\/em>
\n Company\u2019s<\/em>
\n drug components,<\/em>
\n including,<\/em>
\n but<\/em>
\n not<\/em>
\n limited<\/em>
\n to,<\/em>
\n ATH434,<\/em>
\n the<\/em>
\n ability<\/em>
\n of<\/em>
\n the<\/em>
\n Company<\/em>
\n to<\/em>
\n procure<\/em>
\n additional<\/em>
\n future<\/em>
\n sources<\/em>
\n of<\/em>
\n financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company’s drug compounds, including, but not limited<\/em>
\n to,<\/em>
\n ATH434,<\/em>
\n that<\/em>
\n could<\/em>
\n slow<\/em>
\n or prevent products<\/em>
\n coming<\/em>
\n to<\/em>
\n market,<\/em>
\n the uncertainty<\/em>
\n of obtaining patent protection<\/em>
\n for<\/em>
\n the<\/em>
\n Company’s intellectual<\/em>
\n property<\/em>
\n or<\/em>
\n trade<\/em>
\n secrets, the uncertainty of successfully enforcing the Company\u2019s patent rights and the uncertainty of the Company freedom to operate.<\/em>\n <\/p>\n

\n Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks<\/em>
\n only<\/em>
\n as<\/em>
\n of<\/em>
\n the<\/em>
\n date<\/em>
\n on<\/em>
\n which<\/em>
\n it<\/em>
\n is<\/em>
\n made.<\/em>
\n We<\/em>
\n undertake<\/em>
\n no<\/em>
\n obligation<\/em>
\n to<\/em>
\n publicly<\/em>
\n update<\/em>
\n any<\/em>
\n forward-looking<\/em>
\n statement, whether<\/em>
\n written<\/em>
\n or<\/em>
\n oral,<\/em>
\n that<\/em>
\n may<\/em>
\n be<\/em>
\n made<\/em>
\n from<\/em>
\n time<\/em>
\n to<\/em>
\n time,<\/em>
\n whether<\/em>
\n as<\/em>
\n a<\/em>
\n result<\/em>
\n of<\/em>
\n new<\/em>
\n information,<\/em>
\n future<\/em>
\n developments<\/em>
\n or otherwise.<\/em>\n <\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

ATH434 demonstrated clinically meaningful efficacy in modifying disease progression and was well tolerated at both 50 and 75 mg doses MELBOURNE, Australia and SAN FRANCISCO, Sept. 15, 2025 (GLOBE NEWSWIRE) — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (\u201cAlterity\u201d or \u201cthe Company\u201d), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that data from the ATH434-201 randomized, double-blind Phase 2 clinical trial in Multiple System Atrophy (MSA) was presented at the 150th Annual Meeting of the American Neurological Association (ANA), held in Baltimore, MD. A poster, entitled, \u201cATH434 Slowed Disease Progression in a Phase 2 Study in Multiple System Atrophy,\u201d was presented by Daniel Claassen, M.D., M.S., Professor of Neurology at Vanderbilt University Medical Center and … <\/p>\n

Continue reading “Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-886147","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAlterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-presents-ath434-201-phase-2-data-at-the-american-neurological-association-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ATH434 demonstrated clinically meaningful efficacy in modifying disease progression and was well tolerated at both 50 and 75 mg doses MELBOURNE, Australia and SAN FRANCISCO, Sept. 15, 2025 (GLOBE NEWSWIRE) — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (\u201cAlterity\u201d or \u201cthe Company\u201d), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that data from the ATH434-201 randomized, double-blind Phase 2 clinical trial in Multiple System Atrophy (MSA) was presented at the 150th Annual Meeting of the American Neurological Association (ANA), held in Baltimore, MD. A poster, entitled, \u201cATH434 Slowed Disease Progression in a Phase 2 Study in Multiple System Atrophy,\u201d was presented by Daniel Claassen, M.D., M.S., Professor of Neurology at Vanderbilt University Medical Center and … Continue reading "Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-presents-ath434-201-phase-2-data-at-the-american-neurological-association-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-15T11:28:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyODc3NSM3MTQ2MDk0IzIyNTY3MTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-presents-ath434-201-phase-2-data-at-the-american-neurological-association-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-presents-ath434-201-phase-2-data-at-the-american-neurological-association-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting\",\"datePublished\":\"2025-09-15T11:28:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-presents-ath434-201-phase-2-data-at-the-american-neurological-association-annual-meeting\\\/\"},\"wordCount\":1430,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-presents-ath434-201-phase-2-data-at-the-american-neurological-association-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyODc3NSM3MTQ2MDk0IzIyNTY3MTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-presents-ath434-201-phase-2-data-at-the-american-neurological-association-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-presents-ath434-201-phase-2-data-at-the-american-neurological-association-annual-meeting\\\/\",\"name\":\"Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-presents-ath434-201-phase-2-data-at-the-american-neurological-association-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-presents-ath434-201-phase-2-data-at-the-american-neurological-association-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyODc3NSM3MTQ2MDk0IzIyNTY3MTM=\",\"datePublished\":\"2025-09-15T11:28:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-presents-ath434-201-phase-2-data-at-the-american-neurological-association-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-presents-ath434-201-phase-2-data-at-the-american-neurological-association-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-presents-ath434-201-phase-2-data-at-the-american-neurological-association-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyODc3NSM3MTQ2MDk0IzIyNTY3MTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyODc3NSM3MTQ2MDk0IzIyNTY3MTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-presents-ath434-201-phase-2-data-at-the-american-neurological-association-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-presents-ath434-201-phase-2-data-at-the-american-neurological-association-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting - Market Newsdesk","og_description":"ATH434 demonstrated clinically meaningful efficacy in modifying disease progression and was well tolerated at both 50 and 75 mg doses MELBOURNE, Australia and SAN FRANCISCO, Sept. 15, 2025 (GLOBE NEWSWIRE) — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (\u201cAlterity\u201d or \u201cthe Company\u201d), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that data from the ATH434-201 randomized, double-blind Phase 2 clinical trial in Multiple System Atrophy (MSA) was presented at the 150th Annual Meeting of the American Neurological Association (ANA), held in Baltimore, MD. A poster, entitled, \u201cATH434 Slowed Disease Progression in a Phase 2 Study in Multiple System Atrophy,\u201d was presented by Daniel Claassen, M.D., M.S., Professor of Neurology at Vanderbilt University Medical Center and … Continue reading \"Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-presents-ath434-201-phase-2-data-at-the-american-neurological-association-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2025-09-15T11:28:01+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyODc3NSM3MTQ2MDk0IzIyNTY3MTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-presents-ath434-201-phase-2-data-at-the-american-neurological-association-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-presents-ath434-201-phase-2-data-at-the-american-neurological-association-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting","datePublished":"2025-09-15T11:28:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-presents-ath434-201-phase-2-data-at-the-american-neurological-association-annual-meeting\/"},"wordCount":1430,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-presents-ath434-201-phase-2-data-at-the-american-neurological-association-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyODc3NSM3MTQ2MDk0IzIyNTY3MTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-presents-ath434-201-phase-2-data-at-the-american-neurological-association-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-presents-ath434-201-phase-2-data-at-the-american-neurological-association-annual-meeting\/","name":"Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-presents-ath434-201-phase-2-data-at-the-american-neurological-association-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-presents-ath434-201-phase-2-data-at-the-american-neurological-association-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyODc3NSM3MTQ2MDk0IzIyNTY3MTM=","datePublished":"2025-09-15T11:28:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-presents-ath434-201-phase-2-data-at-the-american-neurological-association-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-presents-ath434-201-phase-2-data-at-the-american-neurological-association-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-presents-ath434-201-phase-2-data-at-the-american-neurological-association-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyODc3NSM3MTQ2MDk0IzIyNTY3MTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyODc3NSM3MTQ2MDk0IzIyNTY3MTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-presents-ath434-201-phase-2-data-at-the-american-neurological-association-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/886147","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=886147"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/886147\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=886147"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=886147"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=886147"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}